Market Overview

UPDATE: Bank of America Upgrades Bruker Corporation to Neutral on Improving Fundamentals

Related BRKR
Bruker Corp Has 'Great Story,' But It's Not Time To Jump In Yet
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research

Bank of America upgraded Bruker Corporation (NASDAQ: BRKR) from Underperform to Neutral and raised the price objective from $15.00 to $19.50.

Bank of America noted, "Although we've been positive on BRKR's technology and long-term outlook, we've been cautious on shares chiefly due to the disappointing track record when it came to delivering on margin expansion, cash flow improvements, and profitability targets. While significant work remains, we are encouraged by the recent restructuring initiatives, which include hiring a new CFO and naming new operating group presidents. In addition, mgmt has shown a new willingness to reduce certain investments and prune unprofitable businesses, highlighting a renewed focus on not just growing, but growing profitably."

Bruker Corporation closed at $18.09 on Wednesday.

Latest Ratings for BRKR

Sep 2015Morgan StanleyInitiates Coverage onEqual-weight
Aug 2015Cantor FitzgeraldInitiates Coverage onHold
May 2015William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Analyst Ratings


Related Articles (BRKR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters